Drug–drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors
Cancer Chemotherapy and Pharmacology · 2026
DOI: 10.1007/s00280-025-04855-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Yuki Katsuya und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, 104-0045, Japan. Hauptthemen laut MEDLINE: Losartan, Midazolam, Pioglitazone, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: TAS-115 is an oral multi-kinase inhibitor currently under development for the treatment of osteosarcoma and chronic fibrosing interstitial lung diseases with a progressive phenotype. In this study, we evaluated the effect of multiple administrations of TAS-115 on the pharmacokinetic (PK) changes in CYP2C8, CYP2C9, and CYP3A4 substrates, as well as its anti-tumor efficacy and safety in patients with solid tumors. METHODS: Patients received a single oral dose of pioglitazone (CYP2C8 substrate) followed by a cocktail dose of losartan (CYP2C9 substrate) and midazolam (CYP3A4 substrate), both before and during the period of multiple oral TAS-115 doses to evaluate the impact on individual drug PKs with and without TAS-115. Patients who met the inclusion criteria received multiple administrations of TAS-115 in a 21-day cycle (5 days on, 2 days off) until the treatment discontinuation criteria were met. RESULTS: TAS-115 increased the area under the plasma concentration-time curve from time 0 to infinity (AUCinf) for pioglitazone, losartan, midazolam and 1-hydroxymidazolam by a geometric mean ratio (GMR) of 1% (90% confidence interval: 0.91–1.12), 11% (0.97–1.26), -7% (0.84–1.03) and 5% (0.95–1.15), respectively. No additional or unexpected toxicities occurred. The overall response rate (ORR) was 6.3% and the disease control rate (DCR) was 37.5% for patients with solid tumors, including ORR of 25% and DCR of 50% for four patients with osteosarcoma. CONCLUSION: TAS-115 had a limited impact on drug-drug interactions mediated by CYP2C8, CYP2C9, and CYP3A4. Further, the antitumor efficacy and safety profile of TAS-115 suggest its potential as a treatment option for osteosarcoma. TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: jRCT2031210372, October 11, 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
- Musculoskeletal Oncology Service, Osaka International Cancer Institute, Osaka, 541-8567, Japan.
- Department of Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, 135-8550, Japan.
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, 104-0045, Japan. nbryamam@ncc.go.jp.
Zitieren
APA
Katsuya, Y., Takenaka, S., Takahashi, S., & Yamamoto, N. (2026). Drug–drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04855-9
Vancouver
Katsuya Y, Takenaka S, Takahashi S, Yamamoto N. Drug–drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-025-04855-9
BibTeX
@article{Katsuya2026,
author = {Katsuya, Yuki and Takenaka, Satoshi and Takahashi, Shunji and Yamamoto, Noboru},
title = {Drug–drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
doi = {10.1007/s00280-025-04855-9}
}
EUVIMED